SEVOFLURANE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C4H3F7O
Molecular Weight	200.0548
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FCOC(C(F)(F)F)C(F)(F)F

InChI

InChIKey=DFEYYRMXOJXZRJ-UHFFFAOYSA-N

InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2

HIDE SMILES / InChI

Molecular Formula	C4H3F7O
Molecular Weight	200.0548
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020478s025s026lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/ultane-drug.htm https://www.drugs.com/cdi/sevoflurane.html http://www.wikidoc.org/index.php/Sevoflurane

Sevoflurane is a general anesthetic that is FDA approved for the induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. Sevoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Sevoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase and also binds to the GABA receptor. Common adverse reactions include cardiovascular: bradyarrhythmia, hypotension, gastrointestinal: nausea, vomiting, neurologic: somnolence, psychiatric: agitation, respiratory: cough, interrupted breathing and other: shivering.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
GABA receptor alpha-1 subunit 19 Target ID: CHEMBL1962 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12960553 \| https://www.ncbi.nlm.nih.gov/pubmed/11412290 \| https://www.ncbi.nlm.nih.gov/pubmed/25139222 \| http://www.drugbank.ca/drugs/DB01236	Agonist 2752
GABA receptor alpha-2 subunit 7 Target ID: CHEMBL4956 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12960553 \| https://www.ncbi.nlm.nih.gov/pubmed/25139222	Agonist 2752
GABA-B receptor 32 Target ID: CHEMBL2111463 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9059206	Modulator 846
Glutamate receptor 1 3 Target ID: P42261 Gene ID: 2890.0 Gene Symbol: GRIA1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/22672766 \| http://www.drugbank.ca/drugs/DB01236	Antagonist 2849
Acetylcholine receptor; alpha1/beta1/delta/gamma 3 Target ID: CHEMBL1907588 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9009947	Inhibitor 8504	1.5 mM [IC50]
Serotonin 3a (5-HT3a) receptor 48 Target ID: CHEMBL1899 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11873047 \| https://www.ncbi.nlm.nih.gov/pubmed/20885002	Inhibitor 8504
Glycine receptor (alpha-1/beta) 15 Target ID: CHEMBL2363052 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23565218 \| http://www.drugbank.ca/drugs/DB01236	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 619 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020478s025s026lbl.pdf	Preventing		Approved 8583	ULTANE Approved Use Sevoflurane, USP is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. Sevoflurane, USP should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. Since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane, USP should be used. Launch Date 1995

C_max

Value	Dose	Co-administered	Analyte	Population
26.1 μM DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020478s030lbl.pdf	2.1 % single, respiratory dose: 2.1 % route of administration: Respiratory experiment type: SINGLE co-administered:		FLUORIDE ION plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
25.6 μM DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020478s030lbl.pdf	1.7 % single, respiratory dose: 1.7 % route of administration: Respiratory experiment type: SINGLE co-administered:		FLUORIDE ION plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
33 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020478s030lbl.pdf	2.1 % single, respiratory dose: 2.1 % route of administration: Respiratory experiment type: SINGLE co-administered:		FLUORIDE ION plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
24 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020478s030lbl.pdf	1.7 % single, respiratory dose: 1.7 % route of administration: Respiratory experiment type: SINGLE co-administered:		FLUORIDE ION plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Nav1.7 32	CYP2A6 626 CYP2B6 776 CYP2E1 729

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
Nav1.7 32	inhibitor 4027 Sources: https://link.springer.com/article/10.1007%2Fs00540-011-1167-7	yes [Inhibition 1000 uM]

Drug as victim

Target	Modality	Activity
CYP2A6 626	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/books/NBK534781/	minimal
CYP2B6 776	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/books/NBK534781/	minimal
CYP2E1 729	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/books/NBK534781/	minimal
CYP3A4 1946	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/books/NBK534781/	minimal

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/16368812/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:9130	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9130
ChemicalBook	CB1440979	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1440979
eMolecules	891010	https://www.emolecules.com/cgi-bin/more?vid=891010
MolPort	MolPort-001-775-746	https://www.molport.com/shop/molecule-link/MolPort-001-775-746
ZINC	ZINC000001530810	http://zinc15.docking.org/substances/ZINC000001530810

PubMed

Title	Date	PubMed
Comparison of sevoflurane-nitrous oxide anaesthesia with the conventional intravenous-inhalational technique using bispectral index monitoring.	2001 Apr	11284814
Increased T-wave amplitude after accidental intravascular injection of lidocaine plus bupivacaine without epinephrine in sevoflurane-anesthetized child.	2001 Apr	11273925
Pediatric caudal block with mepivacaine, bupivacaine or a mixture of both drugs: requirement for postoperative analgesia and plasma concentration of local anesthetics.	2001 Feb	11259892
Can anesthesiologic strategies for caesarean section influence newborn jaundice? A retrospective and prospective study.	2001 Feb	11223650
Hepatic failure in a child after acetaminophen and sevoflurane exposure.	2001 Jun	11375824
[The effect of anesthetic technique on recovery from neuromuscular blockade with cisatracurium].	2001 Mar	11333795
The effects of low-flow sevoflurane and isoflurane anesthesia on renal function in patients with stable moderate renal insufficiency.	2001 Mar	11226095
Coagulation assessment in healthy pigs undergoing single xenon anaesthesia and combinations with isoflurane and sevoflurane.	2001 May	11309018

Patents

Sample Use Guides

In Vivo Use Guide

Surgical levels of anesthesia can usually be achieved with concentrations of 0.5 - 3% sevoflurane with or without the concomitant use of nitrous oxide.

Route of Administration: Respiratory

In Vitro Use Guide

Currents elicited by GABA 0.01 mM were increased by low sevoflurane concentrations to 183% and decreased by high sevoflurane concentrations (> 1 mM) to 34% (P < 0.05). Ten- to 90%-rise times of the currents were reduced by sevoflurane concentration dependently. At GABA (1 mM), peak currents and 10-90%-rise times decreased with increasing sevoflurane concentrations.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:55:43 GMT 2025` Edited by `admin` on `Mon Mar 31 17:55:43 GMT 2025`
Record UNII	38LVP0K73A
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SEVOCALM

Preferred Name

English

SEVOFLURANE

Official Name

English

SEVOFLURANE [VANDF]

Common Name

English

SEVOFLO

Brand Name

English

SEVOFLURANE [EMA EPAR VETERINARY]

Common Name

English

SEVOFLURANE [USAN]

Common Name

English

SEVOFLURANE [USP MONOGRAPH]

Common Name

English

SEVOFLURANE [EP MONOGRAPH]

Common Name

English

SEVOFLURANE [USP-RS]

Common Name

English

SEVORANE

Brand Name

English

Sevoflurane [WHO-DD]

Common Name

English

SEVOFLURANE [MART.]

Common Name

English

SEVOFLURANE [MI]

Common Name

English

MR6S4

Code

English

ULTANE

Brand Name

English

SEVOFLURANE [USP IMPURITY]

Common Name

English

NSC-760367

Code

English

SEVOFLURANE [ORANGE BOOK]

Common Name

English

MR-6S4

Code

English

SEVOFLURANE [GREEN BOOK]

Common Name

English

PROPANE, 1,1,1,3,3,3-HEXAFLUORO-2-(FLUOROMETHOXY)-

Systematic Name

English

SEVOFLURANE [JAN]

Common Name

English

sevoflurane [INN]

Common Name

English

SEVOFLURANE [EP IMPURITY]

Common Name

English

Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

N01AB08